The Archives of Bone and Joint Surgery

The Archives of Bone and Joint Surgery

Effects of Biologic Therapies on the Chance of COVID-19 Infection Among Rheumatoid Arthritis and Lupus Patients During the First Wave of the Pandemic

Document Type : RESEARCH PAPER

Authors
Maryam Sahebari 1
Zahra Mirfeizi 1
Kamila Hashemzadeh 1
Ensie Salavati Nik 2
Negar Gholampoor Shamkani 2
1 Rheumatic Diseases Research Center (RDRC), Mashhad Universality of Medical Sciences, Mashhad, Iran
2 Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
10.22038/abjs.2022.60064.2959
Abstract
risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite the effectiveness of using
combined conventional and biological disease-modifying anti-rheumatic drugs(bDMARDs) in managing rheumatic
diseases, there have been concerns that taking biological agents may have an additive effect on getting infected with
COVID-19. This study evaluates the impact of taking biological agents on altering the chance of getting infected with
SARS-CoV-2 in rheumatoloid and lupus patients compared to traditional DMARDs.
Methods: We carried out a cross-sectional survey study from February 2020 to January 2021 on patients diagnosed
with lupus and rheumatid arthritis. COVID-19 infection was confirmed by the presence of symptoms and signs of the disease
and para-clinical findings such as lymphopenia and elevated C-reactive protein (CRP) and positive chest CT scan
or polymerase chain reaction (PCR) of COVID-19.
Results: Out of 591 patients included in this study, 422 (71.4%) had rheumatoid arthritis (RA), and 169 (28.6%) had
systemic lupus erythematosus (SLE). Among them, 56 (9.5%) cases were diagnosed with COVID-19 infection. No
association was found between age, gender, or type of rheumatological diseases and SARS-CoV-2. There was a
significant association between COVID-19 infection and treatment with biological drugs (P-value<0.05) regardless of
the type of rheumatologic disease. Interestingly, the analysis revealed that the type of biologic drug also altered the
chance of COVID-19 infection; In fact, patients who took TNF inhibitors were significantly at a higher risk of disease
than those taking Rituximab (P-value=0.000). Identical results were observed among RA patients (P-value<0.001),
however, all 5 (3%) lupus cases treated with Rituximab infected with covid 19.
Conclusion: This study develops a better understanding of the risk of immunosuppressive medications for SARSCoV-
2 infection. Patients treated with conventional and biological medicine had a higher disease risk than those taking
exclusively conventional drugs. However, more studies are required to deliberate the relation of the reviewed factors
with the severity of COVID-19.
Level of evidence: II
Keywords
Anti-TNFs
Biological DMARDs
COVID-19
Adalimumab
Infliximab
Rituximab
Rheumatoid arthritis (RA)
Systemic lupus erythematous (SLE)
Altebrel
CinnoRA
  1. Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int.2020;40(10):1593-8. doi: 10.1007/s00296-020-04676-4
  2. Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-62. doi: 10.1097/BOR.0000000000000776.
  3. Panjavi B, Kamrani RS, Ghane B. The Ups and Downs of COVID-19 Epidemics for Orthopedic Community. Arch Bone Jt Surg. 2020;8(Supplement 1):218-9. doi: 10.22038/abjs.2020.47734.2343.
  4. Goldblatt F, Chambers S, Rahman A, Isenberg D. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682-9doi: 10.1177/0961203308101019.
  5. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2012; 52(1):53-61. doi: 10.1093/rheumatology/kes305.
  6. Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. J Rheumatol. 2020;47(8):1296. doi: 10.3899/jrheum.200507.
  7. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6. doi: 10.1038/s41586-020-2521-4.
  8. Migkos MP, Kaltsonoudis E, Pelechas E, et al. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int. 2021;41(5):903-9. doi: 10.1007/s00296-021-04818-2.
  9. Michelena X, Borrell H, López-Corbeto M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2020;50(4):564-70. doi: 10.1016/j.semarthrit.2020.05.001.
  10. Dejaco C, Alunno A, Bijlsma JW, et al. Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Ann Rheum Dis. 2021;80(4):518-26. doi: 10.1136/annrheumdis-2020-218697.
  11. Price E, MacPhie E, Kay L, et al. Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. Clin Med (Lond). 2020;20(3):256-61. doi: 10.7861/clinmed.2020-0149.
  12. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. 2020;87(5):439-43. doi: 10.1016/j.jbspin.2020.05.003.
  13. Schoot TS, Kerckhoffs APM, Hilbrands LB, van Marum RJ. Immunosuppressive Drugs and COVID-19: A Review. Front Pharmacol. 2020;11: 1333. doi: 10.3389/fphar.2020.01333.
  14. Calabrese C. COVID-19 and your rheumatology patients. Cleve Clin J Med. 2020. doi: 10.3949/ccjm.87a.ccc027.
  15. Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79(7):988-90. doi: 10.1136/annrheumdis-2020-217948.
  16. Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(11):1393-9. doi: 10.1136/annrheumdis-2020-217984.
  17. Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, et al. Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. J Rheumatol. 2021;48(7):1098-102. doi: 10.3899/jrheum.200755.
  18. Santos CS, Férnandez XC, Moriano Morales C, et al. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe? RMD Open. 2021;7(1):e001439. doi: 10.1136/rmdopen-2020-001439.
  19. Mahmoudi S, Mehdizadeh M, Shervin Badv R, et al. The Coronavirus Disease 2019 (COVID-19) in Children: A Study in an Iranian Children’s Referral Hospital. Infect Drug Resist. 2020;13:2649-55. doi: 10.2147/IDR.S259064.
  20. Salehi-Abari I, Khazaeli S, Salehi-Abari F, Salehi-Abari A. Practical Guideline for Screening the Patients with SARS-CoV-2 Infection and Persian Gulf Criteria for Diagnosis of COVID-19. Advances in Infectious Diseases. 2020;10(03):67. DOI:10.4236/aid.2020.103008
The Archives of Bone and Joint Surgery
Volume 10, Issue 11
November 2022
Pages 946-968

  • Receive Date 31 August 2021
  • Revise Date 05 April 2022
  • Accept Date 07 April 2022